New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
DexCom, Inc. DXCM recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the longest-lasting and most accurate CGM approved in the United States. This ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...
Add Yahoo as a preferred source to see more of our stories on Google. Dexcom is poised to share new data on the benefits of its continuous glucose monitoring technology (CGM), which the company says ...
In addition to improved accuracy, the Dexcom G7 15 Day allows for 15.5 days of wear. The Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM) system ...
BARCELONA, Spain--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results